文献速递肝病

健康信息技术干预减少肝硬化可避免再入院:HEROIC随机对照试验

Health information technology interventions reduce avoidable readmissions in cirrhosis: The HEROIC randomized controlled trial.
PubMed 文献 · Hepatology · 2025-06-11

这项开放标签多中心随机对照试验在3个中心纳入464例肝硬化住院患者及其成年照护者(232对),比较患者伙伴应用(PBA)与标准治疗(SOC)。结果显示SOC组可避免再入院显著高于HIT组(19.8% vs 10.3%,p=0.04),全因再入院也更高(48% vs 30%,p=0.005),作者结论认为PBA与出院后30天可避免再入院降低相关。

要点

  • SOC组可避免再入院19.8% vs HIT组10.3%(p=0.04),OR 2.14(95%CI 1.01-4.54)。
  • SOC组全因再入院48% vs HIT组30%(p=0.005)。
  • 共发送1660条警报,多与肝性脑病相关;多数照护者对应用满意。

核心结论

  • 在3个中心464例肝硬化住院患者及照护者的多中心随机临床试验中,PBA与出院后30天可避免再入院低于SOC相关。

研究设计与样本

  • 开放标签、随机临床试验,在3个中心开展,研究PBA(HIT)与SOC在肝硬化住院患者及成年照护者(成对)中的效果。
  • 初始按1:1:1随机分为SOC、仅HIT和HIT+访视三组,因COVID-19进行非计划性研究重新设计,改为HIT合并组与SOC比较。
  • 共纳入464例受试者(232对):弗吉尼亚联邦大学(VCU)120例、Mayo 40例、退伍军人事务部(VA)72例;每组116对。

主要发现

  • SOC组可避免再入院显著高于HIT组(19.8% vs 10.3%,p=0.04),OR为2.14(95%CI 1.01-4.54)。
  • 去除COVID-19前HIT+访视患者后,SOC组可避免再入院仍显著高于HIT组(19.8% vs 9.3%,p=0.040),OR为2.41(95%CI 1.02-5.69)。
  • SOC组全因再入院高于HIT组(48% vs 30%,p=0.005)。
  • 共发送1660条警报,多与肝性脑病(HE)相关;多数成对者对该应用满意。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Reducing avoidable readmissions in cirrhosis is challenging. Enhanced engagement using health information technology (HIT) interventions and caregivers lowered readmissions in an open-label study of the Patient Buddy App (PBA). Aim: Multicenter trial of PBA versus standard of care (SOC) to reduce avoidable readmissions. APPROACH AND RESULTS: An open-label, randomized clinical trial was performed at 3 sites to study the effect of PBA (HIT) versus SOC in cirrhosis inpatients with adult caregivers (dyads). Initial randomization was 1:1:1 between SOC, HIT only, and HIT+ visits. However, due to COVID-19, an unplanned study redesign required a combined HIT versus SOC. Primary outcome: Avoidable readmissions (decided by a blinded monitoring board). Secondary outcomes were all-cause readmission and stakeholder input. PBA focused on medication adherence, cognitive testing, and symptoms, and was remotely monitored by study staff. In all, 464 subjects (232 dyads) were enrolled [Virginia Commonwealth University (VCU): 120, Mayo: 40, Department of Veterans Affairs (VA): 72; 116 dyads/group]. Avoidable readmissions were significantly higher in SOC versus HIT (19.8% vs. 10.3%, p =0.04) with OR of 2.14 (95% CI 1.01-4.54) and remained significant even after removing pre-COVID HIT+ visits patients (19.8% vs. 9.3%, p =0.040) with OR of 2.41 (95% CI 1.02-5.69). All-cause readmissions were higher in SOC versus HIT (48% vs. 30%, p =0.005). App evaluation/engagement: 1660 alerts were sent; mostly related to HE. Most dyads were satisfied with the app. CONCLUSIONS: In a multicenter randomized clinical trial of 464 cirrhosis inpatients and their CGs across several practice settings, the PBA was associated with lower avoidable readmissions at 30 days post-discharge compared to SOC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Shaw J, Acharya C, Fagan A, et al. Health information technology interventions reduce avoidable readmissions in cirrhosis: The HEROIC randomized controlled trial. Hepatology. 2025. PMID: 40552924. doi:10.1097/HEP.0000000000001424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。